ALS Therapy Development Institute Joins DataCite to Expand Access and Impact of ARC Dataset
Summary
These comprehensive data provide invaluable insights into ALS disease progression and can help identify potential therapeutic targets. This platform enables scientists to analyze ALS data, define patient subsets, and identify promising drug targets.By joining DataCite, ALS TDI will assign Digital Object Identifiers (DOIs) to ARC datasets, ensuring they are permanently accessible, findable, and citable in scientific literature. This enhancement will significantly improve discoverability, especially for researchers unfamiliar with the ARC Data Commons, facilitating broader utilization of this invaluable resource.“Our goal is to maximize the impact of our research on ALS,” said Danielle Boyce, MPH, DPA, Principal Investigator, Real World Evidence at ALS TDI. “By making the ARC dataset more accessible and indexable in global databases, we are opening new doors for collaboration and enabling more scientists to leverage these data in their work to find treatments for ALS.”Strengthening Global Data Governance and Collaboration:DataCite membership not only enables ALS TDI to assign DOIs to its datasets but also provides opportunities to contribute to global data governance and research collaboration. This move aligns ALS TDI with leading research institutions and data-sharing initiatives, amplifying its impact within the scientific community.